Drugs / Universal BCMA-CD19 CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06633042 | Nov 2024 → Oct 2025 overdue | autoimmune disease | Bioray Laboratories | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Universal BCMA-CD19 CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06633042 ↗ |
| Modality | Cell therapy | “Universal CAR-T Cells targeting BCMA” NCT06633042 ↗ |